Surrozen (NASDAQ:SRZN) Director Buys $353,819.20 in Stock

Posted by James Quigley on Jan 23rd, 2026

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) Director Tim Kutzkey acquired 18,052 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the director directly owned 1,016,658 shares in the company, valued at $19,926,496.80. The trade was a 1.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tim Kutzkey also recently made the following trade(s):

On Friday, January 16th, Tim Kutzkey bought 2,562 shares of Surrozen stock. The stock was bought at an average price of $20.00 per share, with a total value of $51,240.00.
On Thursday, January 15th, Tim Kutzkey bought 11,893 shares of Surrozen stock. The shares were bought at an average cost of $19.89 per share, for a total transaction of $236,551.77.
On Wednesday, January 14th, Tim Kutzkey purchased 5,523 shares of Surrozen stock. The stock was bought at an average cost of $19.99 per share, with a total value of $110,404.77.
On Tuesday, January 13th, Tim Kutzkey acquired 12,470 shares of Surrozen stock. The shares were bought at an average price of $19.80 per share, with a total value of $246,906.00.
On Tuesday, January 6th, Tim Kutzkey acquired 15,100 shares of Surrozen stock. The shares were bought at an average cost of $19.89 per share, for a total transaction of $300,339.00.
On Friday, December 5th, Tim Kutzkey bought 30,884 shares of Surrozen stock. The stock was purchased at an average cost of $19.54 per share, for a total transaction of $603,473.36.
On Thursday, December 4th, Tim Kutzkey bought 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, with a total value of $91,365.10.
On Thursday, November 13th, Tim Kutzkey purchased 315,457 shares of Surrozen stock. The shares were purchased at an average cost of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

Surrozen stock opened at $20.00 on Friday. The business’s 50-day simple moving average is $19.26 and its two-hundred day simple moving average is $14.21. The company has a market cap of $171.40 million, a PE ratio of -0.90 and a beta of 0.58. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94.

Surrozen (NASDAQ:SRZN – Get Free Report) last announced its quarterly earnings data on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($2.44). The firm had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. As a group, analysts predict that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SRZN has been the topic of a number of research reports. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Finally, Lifesci Capital raised Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Check Out Our Latest Analysis on SRZN

Institutional Trading of Surrozen

Hedge funds have recently added to or reduced their stakes in the company. Stempoint Capital LP grew its position in Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the period. Braidwell LP acquired a new position in shares of Surrozen in the second quarter worth about $1,252,000. Millennium Management LLC purchased a new stake in shares of Surrozen during the 3rd quarter worth about $1,414,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Surrozen during the 3rd quarter valued at about $889,000. Finally, Armistice Capital LLC purchased a new position in shares of Surrozen in the 2nd quarter valued at about $536,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.